Investor Presentation Q1-Q3 2020
27
Investor presentation First nine months of 2020
Novo Nordisk has a set of strategic aspirations including an
innovation and therapeutic focus
Q+
Further raise the innovation
bar for diabetes treatment
Develop a leading portfolio of
superior treatment solutions for
obesity
Strengthen and
progress the Biopharm
pipeline
Establish presence in
Other serious
chronic diseases
Insulin
%
GLP-1
0
Curative
treatment
5
Glucose-sensitive
Insulin
Oral GLP-1
analogue
10
15
Once-weekly
Weekly GLP-1
analogue
20
Long-
GLP-1
acting
analogue
25
Insulin
analogue
Native GLP-1
30
Weight loss over time
CVD: Cardiovascular disease; CKD: Chronic kidney disease; NASH: Non-alcoholic steatohepatitis
Today's marketed
treatment options
Semaglutide 2.4 mg
Pipeline
Bariatric surgery
Mim8
CVD
Curative
therapy
Non-invasive
therapy
Concizumab
Esperoct
Refixia®
NovoEight®
NovoThirteenⓇ
NovoSeven®
CKD
NASH
Stem Cells
Novo NordiskⓇView entire presentation